AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) An antibody molecule capable of specifically recognizing two regions of the β-A4 peptide/Aβ4, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof, wherein said antibody molecule comprises

(a) a variable V_L-Region comprising complementary determining regions, L-CDR1, L-CDR2, L-CDR3, wherein:

(1) L-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 96, 130-133, 141-143, 160, 175-177, 180, 189, 190, 200, 201, 206-211, and 224;

(2) L-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 97, 144, 161, and 212; and

(3) L-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 16, 18, 20, 75, 77, 79, 81, 83, 85, 87, 95, 98, 102, 103-107, 145, 149-159; 162, 166, 178, 183, 202, 213, 217, 218, 220, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411 and 413; and

(b) a variable V_H-Region comprising complementary determining regions, H-CDR1, H-CDR2, H-CDR3, wherein:

(1) H-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 99, 146, 163, 203, and 214;

(2) H-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 100, 108-129, 134-140, 147, 164, 167-174, 179, 181, 182, 184-188, 191-199, 204, 205, 215, 219, and 221-223; and

(3) H-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 22, 24, 26, 61, 63, 65, 67, 69, 71, 73, 93, 101, 148, 165, 216, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, and 383.

Claim 2. (Original) The antibody molecule of claim 1, wherein said antibody molecule recognizes at least two consecutive amino acids within the two regions of β-A4.

Claim 3. (Currently Amended) The antibody molecule of claim 1, wherein said antibody molecule recognizes in the first region an amino acid sequence ~~comprising:~~ selected from the group consisting of ~~AEFRHD~~, EF, EFR, FR, ~~EFRHDSG, EFRHD or HDSG~~ and SEQ ID NOs: 415 – 418, and in the second region an amino acid sequence ~~comprising:~~ selected from the group consisting of ~~HHQKL,~~ LV~~, LVFFAE, VFFAED, VFFA or FFAEDV~~ and SEQ ID NOs: 419 - 423.

Claim 4. (Previously presented) The antibody molecule of claim 1, wherein said antibody molecule comprises a variable V_H-region as encoded by a nucleic acid molecule as shown in a SEQ ID NO selected from the group consisting of

SEQ ID NOs: 3, 5 and 7, or a variable V_H-region as shown in a SEQ ID NO: selected from the group consisting of SEQ ID NOs: 4, 6 and 8.

Claim 5. (Previously presented) The antibody molecule of claim 1, wherein said antibody molecule comprises a variable V_L-region as encoded by a nucleic acid molecule as shown in a SEQ ID NO selected from the group consisting of SEQ ID NOs: 9, 11 and 13, or a variable V_L-region as shown in a SEQ ID NO selected from the group consisting of SEQ ID NOs: 10, 12 and 14.

Claim 6. (Currently Amended) The antibody molecule of claim 1, wherein said antibody molecule comprises at least one CDR3 amino acid sequence of an V_L-region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 15, 17 or 19, or at least one CDR3 amino acid sequence of an V_L-region as shown in SEQ ID NOs: 16, 18 or 20; and/or wherein said antibody molecule comprises at least one CDR3 amino acid sequence of an V_H-region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 21, 23 or 25, or at least one CDR3 amino acid sequence of an V_H-region as shown in SEQ ID NOs: 22, 24 or 26.

Claim 7. (Previously presented) The antibody molecule of claim 1, wherein said antibody is selected from the group consisting of MSR-3, -7 and -8, and an affinity-matured version of MSR-3, -7 and -8.

Claim 8. (Previously presented) The antibody molecule of claim 1, wherein said antibody molecule is a full antibody (immunoglobulin), a F(ab)-fragment, a $F(ab)_2$-fragment, a single-chain antibody, a chimeric antibody, a CDR-grafted antibody, a bivalent antibody-construct, a synthetic antibody or a cross-cloned antibody.

Claim 9. (Previously presented) The antibody molecule of claim 1, wherein said two regions of β-A4 form a conformational epitope or a discontinuous epitope.

Claim 10. (Cancelled).

Claim 11. (Previously presented) A nucleic acid molecule encoding an antibody molecule according to claim 1.

Claim 12. (Original) A vector comprising the nucleic acid molecule of claim 11.

Claim 13. (Original) A host cell comprising the vector of claim 12.

Claim 14. (Previously presented) A method for the preparation of an antibody molecule comprising culturing the host cell of claim 13 under conditions that allow synthesis of said antibody molecule and recovering said antibody molecule from said culture.

Claim 15. (Previously presented) A pharmaceutical or diagnostic composition comprising an antibody molecule according to claim 1 and a carrier or diluent.

Claim 16. (Previously presented) The composition of claim 15, which is a pharmaceutical composition.

Claims 17-21. (Cancelled).

Claim 22. (Currently Amended) A kit comprising an antibody molecule according to claim 1, a nucleic acid molecule according to claim **[[**16**]]** 11, a vector according to claim **[[**17**]]** 12 or a host cell according to claim **[[**18**]]** 13, wherein the

antibody, nucleic acid, vector or host cell is contained in at least one vial, bottle, container or multicontainer unit.

Claims 23-28. (Cancelled).

Claim 29. (Previously presented) A composition comprising an antibody molecule produced by the method of claim 14.

Claim 30. (Previously presented) The composition of claim 16 further comprising a pharmaceutically acceptable carrier and/or diluent.

Claims 31-40. (Cancelled).

Claim 41. (New) An antibody molecule comprising

(a) a variable V_L-Region comprising complementary determining regions, L-CDR1, L-CDR2, L-CDR3, wherein:

(1) L-CDR1 comprises SEQ ID NO: 143;

(2) L-CDR2 comprises SEQ ID NO: 144; and

(3) L-CDR3 comprises SEQ ID NO: 95; and

(b) a variable V_H-Region comprising complementary determining regions, H-CDR1, H-CDR2, H-CDR3, wherein:

(1) H-CDR1 comprises SEQ ID NO: 146;

(2) H-CDR2 comprises SEQ ID NOs: 192; and

(3) H-CDR3 comprises SEQ ID NOs: 93.

Claim 42. (New) The antibody molecule according to claim 41, wherein the antibody is of the IgG1 subtype.

Claim 43. (New) The antibody molecule according to claim 41, wherein the variable V_H-region comprises SEQ ID NO: 89; and the variable V_L-region region comprises SEQ ID NO: 91.

Claim 44. (New) The antibody molecule according to claim 43, wherein the antibody is of the IgG1 subtype.

Claim 45. (New) The antibody molecule according to claim 41, wherein the variable V_H-region comprises SEQ ID NO: 425; and the variable V_L-region region comprises SEQ ID NO: 91.

Claim 46. (New) The antibody molecule according to claim 45, wherein the antibody is of the IgG1 subtype.

Claim 47. (New) A pharmaceutical composition comprising an antibody molecule according to claim 41 and a pharmaceutically acceptable carrier or diluent.

Claim 48. (New) A pharmaceutical composition comprising an antibody molecule according to claim 44 and a pharmaceutically acceptable carrier or diluent.

Claim 49. (New) A pharmaceutical composition comprising an antibody molecule according to claim 46 and a pharmaceutically acceptable carrier or diluent.